Metropolis Healthcare Reports Financial Results for FY 2026, Highlights Major Acquisitions and Compensation Restructuring
Metropolis Healthcare Limited announced its financial results for the quarter and financial year ending March 31, 2026. The group reported a strong performance, underpinned by significant business acquisitions and structural changes in employee compensation.The consolidated financial statements show substantial growth in revenue and assets for the fiscal year 2026 compared to 2025.
Key Financial Highlights (Consolidated, in Lakhs)
The consolidated financial results for the years ended March 31, 2026, and March 31, 2025, are as follows:| Particulars | March 31, 2026 (Audited) | March 31, 2025 (Audited) |
|---|---|---|
| Total Income | 1,67,143.03 | 1,34,631.60 |
| Total Expenses | 1,40,326.51 | 1,15,546.31 |
| Profit for the year (Total Comprehensive Income) | 14,520.14 | 14,465.35 |
| Total Assets | 2,13,805.46 | 1,86,734.02 |
| Total Equity (excluding NCI) | 1,51,316.06 | 1,33,097.21 |
Administrative Financial Update
Metropolis Healthcare Limited issued a correction regarding its consolidated financial results. The company disclosed that there was an inadvertent error in the figure reported under 'Profit attributable to owners of the Company' in the comparative consolidated financial results for the quarter ended March 31, 2025. The company has since enclosed the revised consolidated financial results, alongside the standalone financial results for the quarter and financial year ended March 31, 2026. The company stated that this administrative correction is not material in nature and does not impact the figures for the current financial year.Major Business Transactions and Acquisitions
The Group's expansion strategy was highlighted by several acquisitions during the year:1. Dapic Metropolis Healthcare Private Limited: The subsidiary completed an acquisition of Dr. Ahujas' Pathology & Imaging Centre on May 23, 2025, for a purchase consideration of Rs. 3,461.00 lakhs.
2. Scientific Metropolis Pathology Private Limited: The acquisition of the business from Dr. Ashok Kumar Sharma was consummated on June 16, 2025. The total purchase consideration was Rs. 6,450.00 lakhs.
3. Dr. RS Patil's Ambika Pathology Laboratory: The transaction for the acquisition of pathology laboratories in Kolhapur, Maharashtra, was completed on September 18, 2025, with a total purchase consideration of Rs 1,700.00 lakhs.
Capital Movements and Dividends
The company undertook significant capital actions during the financial year:- Bonus Shares: The Board approved the issuance and allotment of 15,54,95,826 Bonus Equity Shares in a 3:1 ratio, effective on March 8, 2026.
- Interim Dividend Payouts: The board approved two interim dividend payouts:
* On May 13, 2026, an interim dividend of Re. 1/- per equity share was approved, resulting in a total payout of Rs. 20,73,31,968/-.
Statutory Compliance and Compensation Restructuring
The Group implemented a restructuring of its employee compensation effective April 1, 2026. This move followed the notification of four major Labour Codes by the Government of India—the Code on Wages, 2019; the Industrial Relations Code, 2020; the Code on Social Security, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020—consolidating 29 existing labour laws.The financial impact resulting from these changes was quantified and presented as 'Statutory impact of new Labour Codes' under 'Exceptional Items' in the consolidated statement of profit and loss for the year ended March 31, 2026.
***
Disclaimer: The financial results and data presented are based on the audited and reviewed statements issued by Metropolis Healthcare Limited.
METROPOLIS Stock Price Movement
On Wednesday, Metropolis Healthcare Limited shares edged higher, gaining 0.35% and settling near ₹550. The stock saw robust trading volume, tallying 301,485 shares, signaling strong market participation during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: